Prognostic factors for patients with cirrhosis and kidney dysfunction in the era of MELD: results of a prospective study

被引:57
作者
Schepke, Michael [1 ]
Appenrodt, Beate [1 ]
Heller, Joerg [1 ]
Zielinski, Julia [1 ]
Sauerbruch, Tilman [1 ]
机构
[1] Univ Bonn, Dept Internal Med 1, D-53127 Bonn, Germany
关键词
cirrhosis; hepatorenal syndrome; MELD; prognosis; renal dysfunction;
D O I
10.1111/j.1478-3231.2006.01302.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Hepatorenal syndrome (HRS) is associated with a poor prognosis. The incidence and prognostic impact of kidney dysfunction due to other causes in cirrhotic patients are less well known. The current study prospectively evaluated the incidence and the prognostic relevance of different etiologies of kidney failure in cirrhotic patients. Methods: Eighty-eight consecutive patients with cirrhosis and serum creatinine >= 1.5 mg/dl were enrolled. The etiologies of kidney dysfunction were analyzed, and prognostic factors including Model for End-Stage Liver Disease (MELD) score were evaluated in a multivariate Cox model. Results: HRS was present in 35 (40%) patients (15 HRS 1, 20 HRS 2), followed by renal parenchymal disease (23%), drug-induced kidney dysfunction (19%) and prerenal failure due to bleeding or infections (15%). HRS patients had a significantly higher MELD score and shorter survival. In addition to the MELD score, only HRS 1 was independently predictive for survival. HRS 2 patients had a similar outcome as patients with non-HRS kidney dysfunction. Conclusions: In patients with cirrhosis and renal failure, hepatorenal syndrome is associated with a worse prognosis than kidney dysfunction due to other conditions but only HRS type 1 has independent prognostic relevance in addition to the MELD score in these patients.
引用
收藏
页码:834 / 839
页数:6
相关论文
共 15 条
[1]
MELD score and clinical type predict prognosis in hepatorenal syndrome:: Relevance to liver transplantation [J].
Alessandria, C ;
Ozdogan, O ;
Guevara, M ;
Restuccia, T ;
Jiménez, W ;
Arroyo, V ;
Rodés, J ;
Ginès, P .
HEPATOLOGY, 2005, 41 (06) :1282-1289
[2]
Arroyo V, 1996, HEPATOLOGY, V23, P164, DOI 10.1002/hep.510230122
[3]
Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management [J].
Arroyo, V ;
Colmenero, J .
JOURNAL OF HEPATOLOGY, 2003, 38 :S69-S89
[4]
A prognostic model for predicting survival in cirrhosis with ascites [J].
Fernández-Esparrach, G ;
Sánchez-Fueyo, A ;
Ginès, P ;
Uriz, J ;
Quintó, L ;
Ventura, PJ ;
Cárdenas, A ;
Guevara, M ;
Sort, P ;
Jiménez, W ;
Bataller, R ;
Arroyo, V ;
Rodés, J .
JOURNAL OF HEPATOLOGY, 2001, 34 (01) :46-52
[5]
INCIDENCE, PREDICTIVE FACTORS, AND PROGNOSIS OF THE HEPATORENAL-SYNDROME IN CIRRHOSIS WITH ASCITES [J].
GINES, A ;
ESCORSELL, A ;
GINES, P ;
SALO, J ;
JIMENEZ, W ;
INGLADA, L ;
NAVASA, M ;
CLARIA, J ;
RIMOLA, A ;
ARROYO, V ;
RODES, J .
GASTROENTEROLOGY, 1993, 105 (01) :229-236
[6]
Hepatorenal syndrome [J].
Ginès, P ;
Guevara, M ;
Arroyo, V ;
Rodés, J .
LANCET, 2003, 362 (9398) :1819-1827
[7]
Current concepts -: Management of cirrhosis and ascites [J].
Ginès, P ;
Cárdenas, A ;
Arroyo, V ;
Rodes, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (16) :1646-1654
[8]
GINES P, 1997, KIDNEY INT S61, V52, P77
[9]
A model to predict survival in patients with end-stage liver disease [J].
Kamath, PS ;
Wiesner, RH ;
Malinchoc, M ;
Kremers, W ;
Therneau, TM ;
Kosberg, CL ;
D'Amico, G ;
Dickson, ER ;
Kim, WR .
HEPATOLOGY, 2001, 33 (02) :464-470
[10]
Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome:: A retrospective multicenter study [J].
Moreau, R ;
Durand, F ;
Poynard, T ;
Duhamel, C ;
Cervoni, JP ;
Ichaï, P ;
Abergel, A ;
Halimi, C ;
Pauwels, M ;
Bronowicki, JP ;
Giostra, E ;
Fleurot, C ;
Gurnot, D ;
Nouel, O ;
Renard, P ;
Rivoal, M ;
Blanc, P ;
Coumaros, D ;
Ducloux, S ;
Levy, S ;
Pariente, A ;
Perarnau, JM ;
Roche, J ;
Scribe-Outtas, M ;
Valla, D ;
Bernard, B ;
Samuel, D ;
Butel, J ;
Hadengue, A ;
Platek, A ;
Lebrec, D ;
Cadranel, JF .
GASTROENTEROLOGY, 2002, 122 (04) :923-930